Literature DB >> 33125530

Management of Vaginal Mesh Exposures Following Female Pelvic Reconstructive Surgery.

Cassandra K Kisby1, Brian J Linder2,3.   

Abstract

PURPOSE OF REVIEW: To discuss considerations and current evidence for the diagnosis and management of vaginal mesh exposures following female mesh-augmented anti-incontinence and pelvic organ prolapse surgery. RECENT
FINDINGS: Since the introduction of mesh into female pelvic surgery, various applications have been reported, each with their own unique risk profile. The most commonly encountered mesh-related complication is vaginal mesh exposure. Current evidence on the management of vaginal mesh exposure is largely limited to observational studies and case series, though this is continuing to expand. We present a synthesis of the available data, as well as clinical and surgical approaches to managing this complication. It is important for surgeons to be familiar with the management of vaginal mesh exposures. Depending on the patient's presentation and goals, there is a role for conservative measures, mesh revision, or mesh excision. Further study is warranted to standardize mesh resection techniques and explore non-surgical treatments.

Entities:  

Keywords:  Incontinence surgery; Mesh erosion; Mesh exposure; Midurethral sling; Prolapse surgery; Sacrocolpopexy; Synthetic mesh; Vaginal mesh

Mesh:

Year:  2020        PMID: 33125530     DOI: 10.1007/s11934-020-01002-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  2 in total

Review 1.  Mesh exposure following minimally invasive sacrocolpopexy: a narrative review.

Authors:  Stephanie Deblaere; Jan Hauspy; Karen Hansen
Journal:  Int Urogynecol J       Date:  2022-02-28       Impact factor: 1.932

Review 2.  Application of Acellular Dermal Matrix in Gynaecology-A Current Review.

Authors:  Kaja Skowronek; Wojciech Łabuś; Rafał Stojko; Diana Kitala; Marcin Sadłocha; Agnieszka Drosdzol-Cop
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.